Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/12/2017
SIETES contiene 92152 citas

 
 
 1 a 20 de 130 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
2. Cita con resumen
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22. [Ref.ID 101586]
4.Enlace a cita originalTiene citas relacionadas
5.Tiene citas relacionadas
Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, Demets D, Evans S, Law M, McMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercok P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532-61. [Ref.ID 100988]
6.Enlace a cita originalTiene citas relacionadas
Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA 2016;316:1979-81. [Ref.ID 100987]
7.Enlace a cita originalTiene citas relacionadas
Greenland P, Bonow RO. Interpretation and use of another statin guideline. JAMA 2016;316:1977-9. [Ref.ID 100986]
8.Enlace a cita originalTiene citas relacionadas
Gurwitz JH, Go AS, Fortmann SP. Statins for primary prevention in older adults: uncertainty and the need for more evidence. JAMA 2016;316:1971-2. [Ref.ID 100985]
9.Enlace a cita originalTiene citas relacionadas
Thompson PD. What to believe and do about statin-associated adverse efects. JAMA 2016;316:1969-70. [Ref.ID 100984]
10.Enlace a cita originalTiene citas relacionadas
Rodríguez F, Harrington RA. Cholesterol, cardiovascular risk, statins, PCSK9 inhibitors, and the future of LDL-C lowering. JAMA 2016;316:1967-8. [Ref.ID 100983]
11. Cita con resumen
Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Malhotra A, Mascitelli L, McCully KS, Ogushi Y, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R. Lack of an association or an inverse association between low-density lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open 2016:28 de junio. [Ref.ID 100445]
12. Cita con resumen
Levin S, Wells C, Barnard N. Dietary Cholesterol and Blood Cholesterol Concentrations. JAMA 2015;314:2083-4. [Ref.ID 99688]
13. Cita con resumen
Kastelein JJP, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchel Y. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet 2015;385:2153-61. [Ref.ID 99163]
14. Cita con resumen
Husten L. New U.S. guidelines will lift limits on dietary cholesterol. Physician's First Watch 2015:12 de febrero. [Ref.ID 98775]
15.Enlace a cita original Cita con resumen
Pencina MJ, Navar-Boggan AM, D'Agostino RB, Williams K, Neely B, Sniderman AD, Peterson ED. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370:1422-31. [Ref.ID 97311]
16.Tiene citas relacionadas
Guallar E, Laine C. Controversy over clinical guidelines: listen to the evidence, not the noise. Ann Intern Med 2014;160:361-2. [Ref.ID 97294]
18.Tiene citas relacionadas Cita con resumen
Downs J, Good C. New cholesterol guidelines: has Godot finally arrived?. Ann Intern Med 2014;160:354-5. [Ref.ID 97292]
19.Tiene citas relacionadas Cita con resumen
The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12. [Ref.ID 97194]
20.Tiene citas relacionadas Cita con resumen
Seleccionar todas
 
 1 a 20 de 130 siguiente >>